NeoGenomics announced expanded Medicare coverage for its RaDaR ST molecular residual disease (MRD) assay to include immunotherapy monitoring for late-stage solid tumors. This expands the assay's market reach and potential revenue streams by adding a new, significant indication for its use.
NeoGenomics' RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from CMS' MolDX program. This new coverage allows for the use of RaDaR ST in monitoring the response to immune-checkpoint inhibitor therapy in patients with late-stage solid tumors, adding to its existing Medicare-covered indications. This is a positive development for NeoGenomics as it broadens the addressable market for its diagnostic product, potentially leading to increased sales and revenue. In the short term, this could lead to a positive sentiment boost for NEO stock. Long-term, it solidifies RaDaR ST's position in the oncology diagnostics market and enhances the company's competitive edge, offering an opportunity for sustained growth as immunotherapy use expands.